Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2022 19:35 ET | Source: Taysha Gene Therapies, Inc.

Taysha Gene Therapies to Host Conference Call to Discuss Astellas Pharma’s Strategic Investment to Support the Development of Taysha’s AAV-based Gene Therapy Programs

DALLAS, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
October 24, 2022 19:30 ET | Source: Taysha Gene Therapies, Inc.

Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha’s AAV-based Gene Therapy Programs

- Taysha Gene Therapies is an emerging leader in the development of AAV gene therapies; new collaboration aimed at enhancing development of two of Taysha’s novel product candidates for rare monogenic...
October 06, 2022 07:00 ET | Source: Taysha Gene Therapies, Inc.

Taysha Gene Therapies Announces Presentations at the Upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT)

DALLAS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
August 11, 2022 07:00 ET | Source: Taysha Gene Therapies, Inc.

Taysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

TSHA-120 treated patients in GAN demonstrated durable improvement and recoverability of sensory nerve amplitude potential (SNAP), a definitive clinical endpoint, compared to natural history TSHA-120...
August 09, 2022 17:22 ET | Source: Taysha Gene Therapies, Inc.

Taysha Gene Therapies to Release Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11

DALLAS, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
August 01, 2022 07:00 ET | Source: Taysha Gene Therapies, Inc.

Taysha Gene Therapies to Participate in Upcoming August Investor Conferences

BTIG Biotechnology Conference on August 8, 2022 at 12:00 pm ET 2022 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022 at 9:45 am ET DALLAS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Taysha...
July 06, 2022 07:00 ET | Source: Taysha Gene Therapies, Inc.

Taysha Gene Therapies to Participate in Upcoming William Blair Biotech Focus Conference 2022

DALLAS, July 06, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
June 13, 2022 08:39 ET | Source: Taysha Gene Therapies, Inc.

Taysha Gene Therapies Announces Annual Stockholder Meeting

DALLAS, June 13, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
June 02, 2022 07:00 ET | Source: Taysha Gene Therapies, Inc.

Taysha Gene Therapies to Participate in Upcoming June Investor Conferences and Convention

Jefferies Healthcare Conference on June 8, 2022 at 9:30 am ET Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022 at 11:20 am PT BIO International Convention on June 15, 2022 at...
May 16, 2022 07:00 ET | Source: Taysha Gene Therapies, Inc.

Taysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update

Initiated clinical development of TSHA-102 for Rett Syndrome under recently approved Clinical Trial Application (CTA) with preliminary Phase 1/2 data expected by year-end 2022 Received Orphan Drug...